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We evaluated whether ejaculatory dysfunction induced with a selective a1A-blocker influenced
orgasm. Fifteen healthy male volunteers took silodosin or a placebo in a randomized, double-blind
crossover design. We investigated the ejaculatory volume before and after administration of the
agents. After each ejaculation, participants self-reported the answers to an original questionnaire,
which was about discomfort on ejaculation, orgasm and satisfaction with the discomforting
ejaculation. All participants on silodosin had a complete lack of seminal emission and expulsion.
All participants felt orgasm in spite of a complete lack of seminal emission. Of the 15, 12 (80%) who
had a somewhat uncomfortable feeling during orgasm were dissatisfied with this feeling, although 9
of the 12 reported that its degree was mild. Orgasm is preserved regardless of the loss of seminal
emission with silodosin administration. Although most participants reported mild discomfort
during orgasm, they were greatly dissatisfied with the loss of seminal emission.
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Introduction
The use of a1-adrenoceptor antagonists (a1-block-
ers) is widely accepted as the first-line treatment for
lower urinary tract symptoms suggestive of benign
prostatic hyperplasia.
1–5 Recent studies have high-
lighted the influence of a1-blockers on ejaculatory
function.
6–10 A loss of seminal emission has been
recently postulated as one of the mechanisms of
abnormal ejaculation.
7,8 Highly selective a1-adreno-
ceptor subtype-A antagonists (a1A-blockers) cause a
high incidence of ejaculatory dysfunction. However,
the orgasm and feeling during ejaculatory dysfunc-
tion with a1-blocker administration have not been
fully assessed.
11–13 In addition, even the general
physiology underlying orgasm has not been com-
pletely elucidated.
14 As an another new problem
with regard to orgasm, climacturia after radical
prostatectomy has been noticed recently, but its
mechanism has not been completely elucidated.
14,15
Therefore, study of orgasm-related issues will be
necessary to clarify the physiology of orgasm not
only during normal, but also abnormal ejaculatory
conditions.
Silodosin is a new highly selective a1A-blocker
launched in 2006 in Japan and approved by the
Food and Drug Administration in 2008 in the United
States. The selectivity of silodosin towards the
a1A-adrenoceptor vs the a1B-adorenoceptor sub-
type was reported to be 38 times higher than that
of tamsulosin hydrochloride.
16 We reported earlier
that silodosin induced a complete lack of seminal
emission in healthy volunteers.
8 In this context, we
evaluated the status of orgasm and feeling during
ejaculatory dysfunction induced with the selective
a1A-blocker in healthy volunteers.
Materials and methods
Fifteen healthy male urologists in our department
voluntarily participated in the study. Details of
ejaculatory profiles and methods of collection have
been described earlier.
8 In brief, this study used a
double-blind, placebo controlled, randomized,
crossover design (Figure 1). The median age of the
participants was 32 years (range 26–47years). We
used silodosin, a new highly selective a1A-blocker
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Placebos were prepared by filling empty silodosin
capsules with lactose in our laboratory. Baseline
ejaculatory profiles were collected by masturbation
after 72h of abstinence (from Days 0 to 3) before
administration of silodosin or the placebo. In the
study, 4mg of silodosin or a placebo consisting of
lactose with a dosage identical to that of the drug
was given twice daily to participants for 3 days. We
evaluated the ejaculatory volume and sperm count
in the urine after ejaculation. We defined anejacula-
tion as a 100% decrease in ejaculation volume
compared with the baseline ejaculatory profile as in
earlier reports.
6,8 After each ejaculation, participants
self-reported the answers to an original question-
naire composed of questions to evaluate ejaculatory
function, including orgasm and feeling (see Appen-
dix). All samples were collected by masturbation.
All participants adhered to the schedule for ejacula-
tion by masturbation and did not engage in inter-
course during the study.
Results of ejaculatory profiles are expressed as
mean±s.d. and were considered to be statistically
significant if Po0.05. The changes of parameters
were tested using the Wilcoxon signed-ranks test.
Statistical analyses were performed using StatView
5.0 for Windows (SAS Institute, Cary, NC, USA).
This study was approved by the Ethics Committee
of Sapporo Medical University on 18 June 2006.
Written informed consent was obtained from all
participants.
Results
Ejaculatory dysfunction
All participants on silodosin had a complete lack of
seminal emission and expulsion of semen from
the urethra (semen volume at baseline: 2. 9±1.3ml,
and after silodosin administration: 0ml, Po0.001)
(Figure 2). On the other hand, there was no
significant change in ejaculation with placebo
administration in any participant (semen volume
at baseline: 3.0±1.5ml, and after placebo adminis-
tration: 2.8±1.1ml, P¼0.346). There were no
sperms in urine after ejaculation under silodosin
administration in any participant. Thus, the ejacu-
latory dysfunction caused by silodosin was a loss of
Figure 1 Study design for analysing ejaculation. Black arrows
indicated a given point of ejaculation for semen analysis. White
arrows indicated a given point of ejaculation for ensuring the
same abstinence period.
Figure 2 The results of semen analysis. P-values were derived from statistical analysis using the Wilcoxon signed-ranks test.
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days after completion of silodosin, ejaculatory
volume recovered to the baseline level (semen
volume at the recovery: 2.7±1.4ml vs that at the
baseline: P¼0.637). These results for ejaculatory
dysfunction have been reported earlier.
8
Orgasm
All participants had sexual activity over the earlier
month (Q1, Table 1). All participants who had
silodosin felt discomfort on ejaculation, whereas
none with the placebo did (Q2). In the question-
naire, participants gave details of orgasm if they
felt discomfort during ejaculation (see Appendix).
Therefore, only participants with silodosin an-
swered the questions about satisfaction with ejacu-
latory discomfort, orgasm and the volume of semen
(Q3–Q7).
All participants with silodosin were dissatisfied
with the discomfort in terms of ejaculation, although
the degree varied (Q3, Table 2). Although all partici-
pants with silodosin reported orgasm in spite of a
complete lack of seminal emission and expulsion,
12 subjects (80%) had a somewhat unusual feeling
during orgasm with ejaculatory dysfunction (Q4).
However, the orgasm with some discomfort was not
so big a problem during ejaculatory dysfunction
(Q5). On the other hand, the complete loss of
seminal volume (anejaculation) was judged to be a
big problem by almost all participants (Q6 and Q7).
Discussion
Orgasm coincides with the moment of ejaculation in
normal conditions and is the result of cerebral
processing of pudendal nerve sensory stimuli. These
stimuli are produced by increased pressure in the
posterior urethra, sensory stimuli arising from the
verumontanum and contraction of the urethral bulb
and accessory sexual organs.
17 Orgasm is enhanced
by various events, such as the emission and
ejaculatory processes.
18 In this study, in spite of
anejaculation, orgasm was preserved, although
participants reported a slightly unusual feeling.
When the orgasm with ejaculatory dysfunction
induced by silodosin administration occurred, the
increased pressure in the posterior urethra never
happened because of the complete lack of seminal
emission and expulsion. In addition, the sensory
stimuli arising from the verumontanum did not
occur because semen did not pass through the
urethra. The complete lack of seminal emission
suggested that the contraction of seminal vesicles
was also suppressed. It is speculated that orgasm is
induced by only the contraction of the urethral bulb,
which may be maintained even under silodosin
administration.
It is known that prepubertal children feel orgasm
even without ejaculation. Orgasm without ejacula-
tion is in fact named coitus reservatus.
19 In addition,
Table 1 Answers to the question about sexual activity and the
felling of ejaculation with agent administration
Q1. Did you have sexual activity over the past month?
Yes No
Placebo 15 (100%) 0 (0%)
Silodosin 15 (100%) 0 (0%)
Q2. Did you feel discomfort when you ejaculated during the
sexual activity?
Yes No
Placebo 0 (0%) 15 (100%)
Silodosin 15 (100%) 0 (0%)
Table 2 Answers to the questions about satisfaction with ejaculatory discomfort, orgasm and volume of semen with silodosin
administration
Q3. If you had to spend the rest of your life with your ejaculatory discomfort as it is now, how would you feel?
Very satisfied Satisfied Mostly satisfied Neutral or mixed Mostly dissatisfied Dissatisfied Very dissatisfied
0 (0%) 0 (0%) 0 (0%) 1 (6.7%) 1 (6.7%) 7 (46.7%) 6 (40.0%)
Q4. Did you have a somewhat uncomfortable feeling during orgasm when you ejaculated?
Not at all Slightly Moderately Very
3 (20.0%) 9 (60.0%) 0 (0%) 3 (20.0%)
Q5. How much has a feeling during orgasm with some discomfort been a problem for you?
No problem Small problem Moderate problem Big problem
3 (20.0%) 6 (40.0%) 4 (26.7%) 2 (13.3%)
Q6. How is the volume of semen when you ejaculate?
Normal Slightly decreased Very decreased None at all
0 (0%) 0 (0%) 0 (0%) 15 (100%)
Q7. How much has the volume of semen been a problem for you?
No problem Small problem Moderate problem Big problem
0 (0%) 2 (13.3%) 0 (0%) 13 (86.7%)
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can feel orgasm without seminal emission. When
the post-radical prostatectomy patient feels orgasm,
pudendal nerve sensory stimulation resulting from
only smooth muscle contraction of the urethral bulb
occurs. Therefore, it is not strange that orgasm can
occur during ejaculatory dysfunction.
In this study, all participants were greatly dis-
satisfied with the ejaculatory dysfunction induced
by the a1A-blocker. Participants reported only mild
discomfort with the orgasm during ejaculatory
dysfunction. However, the reduced amount of se-
men provoked a big problem. As it has been reported
that a strong decline in ejaculatory volume is
associated with reduced sexual pleasure,
19 it is
speculated that the semen volume, but not the
feeling of orgasm, mainly affects the satisfaction of
ejaculation by masturbation.
In this study, we used the term ‘anejaculation’ to
indicate a complete loss of ejaculation volume, as
defined in earlier reports.
6,8 However, the terminol-
ogy of ejaculatory dysfunction has not been stan-
dardized, as ejaculatory dysfunction with selective
a1A-blockers has been noticed. We should create
new terminology for ejaculatory dysfunction in-
duced by highly selective a1A-blockers.
These are some limitations in this study. One of
the problems was that we used an original ques-
tionnaire, which was not fully validated. The four-
item version of Male Sexual Health Questionnaire
(MSHQ-EjD Short Form) is a validated questionnaire
for ejaculatory dysfunction in English.
20 Although
the MSHQ-EjD Short Form includes three ejacula-
tory function items and one ejaculation bother item,
there is no item about the quality of orgasm.
Moreover, the MSHQ has not been validated in
Japanese yet. In this study, we wanted to determine
what ejaculatory problems induced the most im-
paired quality of ejaculation, for example the
amount of semen. In this context, there is no
appropriate questionnaire to evaluate the quality of
orgasm associated with ejaculatory dysfunction.
This is the reason for not using the validated
questionnaire to evaluate the quality of orgasm in
this study. However, we should certainly validate
the questionnaire for assessing the status of orgasm
used in this study in the future.
Conclusions
Orgasm is preserved regardless of anejaculation
with silodosin administration. Although most parti-
cipants reported mild discomfort during orgasm,
they were greatly dissatisfied with their ejaculatory
status mainly because of the reduced amount of
semen. These findings suggest that the emission of
semen and its passage through the urethra are not
necessary for orgasm.
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Appendix
Questionnaire about ejaculatory dysfunction sexual
activity includes intercourse, caressing, foreplay
and masturbation
Q1. Did you have sexual activity over the past
month? (Yes/No)
* P l e a s ea n s w e rQ 2o n l yi fy o ua n s w e r e d‘ Y E S ’t oQ 1.
Q2. Did you feel discomfort when you ejaculated
during the sexual activity? (Yes/No)
*Please answer the following question if you who
answered ‘YES’ to Q2.
Q3. If you had to spend the rest of your life with
your ejaculatory discomfort as it is now, how
would you feel?
(Very satisfied, Satisfied, Mostly satisfied, Neutral
or mixed, Mostly dissatisfied, Dissatisfied, Very
dissatisfied).
Q4. Did you have a somewhat uncomfortable
feeling during orgasm when you ejaculated?
(Not at all, Slightly, Moderately, Very).
Q5. How much has a feeling during orgasm with
some discomfort been a problem for you?
(No problem, Small problem, Moderate problem,
Big problem).
Q6. How is the volume of semen when you
ejaculate?
(Normal, Slightly decreased, Very decreased,
None at all).
Q7. How much has the volume of semen been a
problem for you?
(No problem, Small problem, Moderate problem,
Big problem).
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